Axsome Therapeutics Hosts Frontiers in Brain Health R&D Day Reviewing Industry-Leading Late-Stage CNS Pipeline
Provided By GlobeNewswire
Last update: Jul 21, 2025
Comprehensive review of broad pipeline targeting Alzheimer’s disease agitation, depression, narcolepsy, fibromyalgia, ADHD, and smoking cessation, with new data analyses
Read more at globenewswire.com109.215
+0.47 (+0.43%)
Find more stocks in the Stock Screener
AXSM Latest News and Analysis
